{
    "organizations": [],
    "uuid": "5035547cda8843e50b67b94c741f9c3af7d6fe71",
    "author": "",
    "url": "https://www.reuters.com/article/brief-valneva-and-emergent-biosolutions/brief-valneva-and-emergent-biosolutions-start-phase-1-clinical-study-to-evaluate-vaccine-candidate-against-zika-virus-idUSASM000JQZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 24 PM / Updated 10 minutes ago BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus Reuters Staff 1 Min Read Feb 26 (Reuters) - VALNEVA SE: * EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS * ‍INITIAL DATA FROM TRIAL ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019​ * AFTER PHASE 1 DATA, EMERGENT HAS OPTION TO DEVELOP VACCINE UNDER LICENSE AGREEMENT WITH VALNEVA AT EUR 5 MILLION​ * LICENSE ‍AGREEMENT PROVIDES VALNEVA POTENTIAL ADDITIONAL MILESTONE PAYMENTS OF UP TO EUR 44 MILLION​ * LICENSE ‍AGREEMENT TO GIVE CO RIGHT TO NEGOTIATE WITH EMERGENT EXCLUSIVE COMMERCIALIZATION RIGHTS IN EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
    "published": "2018-02-26T23:24:00.000+02:00",
    "crawled": "2018-02-26T23:44:05.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "emergent",
        "biosolutions",
        "start",
        "phase",
        "clinical",
        "study",
        "evaluate",
        "vaccine",
        "candidate",
        "zika",
        "virus",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "valneva",
        "se",
        "emergent",
        "biosolutions",
        "valneva",
        "initiate",
        "phase",
        "clinical",
        "study",
        "evaluate",
        "vaccine",
        "candidate",
        "zika",
        "virus",
        "data",
        "trial",
        "expected",
        "available",
        "late",
        "early",
        "phase",
        "data",
        "emergent",
        "option",
        "develop",
        "vaccine",
        "license",
        "agreement",
        "valneva",
        "eur",
        "license",
        "provides",
        "valneva",
        "potential",
        "additional",
        "milestone",
        "payment",
        "eur",
        "license",
        "give",
        "co",
        "right",
        "negotiate",
        "emergent",
        "exclusive",
        "commercialization",
        "right",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}